Found: 16
Select item for more details and to access through your institution.
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 3, p. 194, doi. 10.1016/j.clml.2023.11.001
- By:
- Publication type:
- Article
P-206: SELECT Trial in Progress: an open-label, phase 2 study of Carfilzomib, Pomalidomide, and Dexamethasone in patients with first or second relapse of Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S152, doi. 10.1016/S2152-2650(21)02333-8
- By:
- Publication type:
- Article
P-177: Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma: a multicohort analysis from phase III trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S133, doi. 10.1016/S2152-2650(21)02304-1
- By:
- Publication type:
- Article
Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e208, doi. 10.1016/j.clml.2019.09.346
- By:
- Publication type:
- Article
Comparison of three different assays demonstrates heterogeneity in determination of serum free light chains - implications on diagnostic and therapeutic monitoring of multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e181, doi. 10.1016/j.clml.2019.09.303
- By:
- Publication type:
- Article
Prospective monitoring of immune signatures in newly diagnosed high risk multiple myeloma patients under treatment with Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd): First results of the GMMG-CONCEPT trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e141, doi. 10.1016/j.clml.2019.09.236
- By:
- Publication type:
- Article
Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II, multicenter GMMG-CONCEPT trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e17, doi. 10.1016/j.clml.2019.09.024
- By:
- Publication type:
- Article
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 2, p. 696, doi. 10.1007/s12325-023-02738-0
- By:
- Publication type:
- Article
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 5, p. 2412, doi. 10.1007/s12325-023-02480-7
- By:
- Publication type:
- Article
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00805-x
- By:
- Publication type:
- Article
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41408-019-0267-8
- By:
- Publication type:
- Article
Deteriorated Executive Functions in Patients with Successful Surgery for Pituitary Adenomas Compared with Other Chronically Ill Patients.
- Published in:
- Journal of the International Neuropsychological Society, 2011, v. 17, n. 2, p. 369, doi. 10.1017/S1355617710001645
- By:
- Publication type:
- Article
Younger age is a good predictor of better executive function after surgery for pituitary adenoma in adults.
- Published in:
- Journal of the International Neuropsychological Society, 2009, v. 15, n. 5, p. 803, doi. 10.1017/S1355617709990324
- By:
- Publication type:
- Article
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial.
- Published in:
- Cancers, 2023, v. 15, n. 18, p. 4667, doi. 10.3390/cancers15184667
- By:
- Publication type:
- Article
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4856, doi. 10.3390/cancers13194856
- By:
- Publication type:
- Article